Iqvia Stock Price, News & Analysis (NYSE:IQV)

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) released its earnings results on Wednesday, July, 24th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.38 by $0.01. The medical research company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.70 billion. Iqvia had a return on equity of 15.95% and a net margin of 2.31%. Iqvia's quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.29 earnings per share. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for Iqvia.

Iqvia will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Iqvia updated its FY19 earnings guidance on Wednesday, July, 24th. The company provided EPS guidance of $6.25-6.45 for the period, compared to the Thomson Reuters consensus estimate of $6.33. The company issued revenue guidance of $11.00-1.15 billion, compared to the consensus revenue estimate of $11.02 billion.

18 analysts have issued 1 year price targets for Iqvia's shares. Their forecasts range from $136.38 to $180.00. On average, they anticipate Iqvia's share price to reach $164.49 in the next year. This suggests a possible upside of 14.9% from the stock's current price. View Analyst Price Targets for Iqvia.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

Press coverage about IQV stock has been trending somewhat positive on Monday, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iqvia earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Iqvia.

Iqvia saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 4,630,000 shares, an increase of 42.9% from the August 30th total of 3,240,000 shares. Based on an average trading volume of 1,240,000 shares, the short-interest ratio is currently 3.7 days. Currently, 2.6% of the shares of the company are short sold. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), Micron Technology (MU), Workday (WDAY), NIC (EGOV) and Zoetis (ZTS).

Iqvia's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.22%), Artemis Investment Management LLP (0.14%), Robeco Institutional Asset Management B.V. (0.11%), Arvest Bank Trust Division (0.11%), Envestnet Asset Management Inc. (0.10%) and Howard Capital Management (0.06%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Zurcher Kantonalbank Zurich Cantonalbank, Robeco Institutional Asset Management B.V., Artemis Investment Management LLP, Arvest Bank Trust Division, CIBC Private Wealth Group LLC, Gateway Investment Advisers LLC and Enlightenment Research LLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

IQV stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio, State of Alaska Department of Revenue, Envestnet Asset Management Inc., Oakbrook Investments LLC, Covenant Asset Management LLC, Middleton & Co Inc MA, Whittier Trust Co. and Tuttle Tactical Management. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $143.14.

Iqvia has a market capitalization of $28.04 billion and generates $10.41 billion in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.View Additional Information About Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]